论文部分内容阅读
目的观察补中气、升清阳法联合四联疗法根治幽门螺杆菌(Hp)阳性慢性脾胃病的临床疗效。方法选取2012年1月—2014年6月郑州市中医院门诊部收治的76例Hp阳性慢性脾胃病患者为研究对象,随机数字表法分为观察组和对照组,每组38例。对照组给予四联疗法治疗,观察组另联合补中气、升清阳法治疗,观察两组治疗后临床疗效、胃酸分泌功能[基础胃酸分泌量(BAO)、最大胃酸分泌量(MAO)、高峰胃酸分泌量(PAO)]及药物不良反应。结果治疗后观察组临床总有效率86.84%与对照组65.79%相比差异有统计学意义(P<0.05);治疗后两组BAO、MAO、PAO均较治疗前显著降低,观察组治疗后BAO、MAO、PAO均低于对照组,差异有统计学意义(均P<0.05);两组治疗后药物不良反应比较差异无统计学意义(P>0.05)。结论补中气、升清阳法联合四联疗法根治Hp阳性慢性脾胃病的临床疗效显著并有效抑制患者胃酸分泌,两种疗法的结合有临床应用价值。
Objective To observe the clinical efficacy of Bu Zhongqi and Shengqingyang combined with quadruple therapy in the treatment of Helicobacter pylori (Hp) -positive chronic spleen-stomach disease. Methods From January 2012 to June 2014, 76 patients with Hp-positive chronic spleen-stomach disease admitted in the Outpatient Department of Zhengzhou TCM Hospital were enrolled. The random number table was divided into observation group and control group, with 38 cases in each group. The control group was treated with quadruple therapy. The observation group was additionally treated with Bu Zhongqi and Shengyang Decoction. The curative effect, gastric acid secretion function (basic gastric acid secretion, maximal gastric acid secretion, Peak gastric acid secretion (PAO)] and adverse drug reactions. Results After treatment, the total clinical effective rate was 86.84% in the observation group compared with 65.79% in the control group (P <0.05); BAO, MAO and PAO in the two groups were significantly lower than those before treatment , MAO, PAO were lower than the control group, the difference was statistically significant (both P <0.05); two groups of post-treatment adverse drug reaction was no significant difference (P> 0.05). Conclusions Buzhongqi and Shengqiyang combined with quadruple therapy have a significant clinical curative effect and significant inhibitory effect on gastric acid secretion in Hp-positive patients with chronic spleen-stomach disease. The combination of the two therapies has clinical value.